Song P. Rudan D. Zhu Y. et al.

Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis.

Lancet Glob Health. 7: e1020-e1030Fowkes F.G. Rudan D. Rudan I. et al.

Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.

Lancet. 382: 1329-1340Chen Q. Li L. Chen Q. et al.

Critical appraisal of international guidelines for the screening and treatment of asymptomatic peripheral artery disease: a systematic review.

BMC Cardiovasc Disord. 19: 17

IDF diabetes atlas, 10th edition., Brussels, Belgium. 2021.

() ()Stoberock K. Kaschwich M. Nicolay S.S. et al.

The interrelationship between diabetes mellitus and peripheral arterial disease.

VASA. 50: 323-330Kreutzburg T. Peters F. Kuchenbecker J. et al.

Editor's choice - the germanvasc score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease.

Eur J Vasc Endovasc Surg. 61: 248-256Baubeta Fridh E. Andersson M. Thuresson M. et al.

Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study.

Eur J Vasc Endovasc Surg. 54: 480-486Kotov A. Peters F. Debus E.S. et al.

The prospective GermanVasc cohort study.

VASA Z Gefasskrankheiten. 50: 446-452Kreutzburg T. Peters F. Riess H.C. et al.

Editor's choice - comorbidity patterns among patients with peripheral arterial occlusive disease in germany: a trend analysis of health insurance claims data.

Eur J Vasc Endovasc Surg. 59: 59-66Mach F. Baigent C. Catapano A.L. et al.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 41: 111-188McDonagh T.A. Metra M. Adamo M. et al.

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

Eur Heart J. 42: 3599-3726Visseren F.L.J. Mach F. Smulders Y.M. et al.

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

Eur Heart J. 42: 3227-3337Cosentino F. Grant P.J. Aboyans V. et al.

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Eur Heart J. 41: 255-323

9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021.

Diabetes Care. 44: S111-S124Zinman B. Wanner C. Lachin J.M. et al.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

N Engl J Med. 373: 2117-2128Wiviott S.D. Raz I. Bonaca M.P. et al.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

N Engl J Med. 380: 347-357Perkovic V. Jardine M.J. Neal B. et al.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

N Engl J Med. 380: 2295-2306Neal B. Perkovic V. Matthews D.R.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

N Engl J Med. 377: 2099Hollander P. Liu J. Hill J. et al.

Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study.

Diabetes Ther. 9: 193-207Cannon C.P. Pratley R. Dagogo-Jack S. et al.

Cardiovascular outcomes with ertugliflozin in type 2 diabetes.

N Engl J Med. 383: 1425-1435Fioretto P. Del Prato S. Buse J.B. et al.

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.

Diabetes Obes Metab. 20: 2532-2540McMurray J.J.V. Solomon S.D. Inzucchi S.E. et al.

Dapagliflozin in patients with heart failure and reduced ejection fraction.

N Engl J Med. 381: 1995-2008Packer M. Anker S.D. Butler J. et al.

Cardiovascular and renal outcomes with empagliflozin in heart failure.

N Engl J Med. 383: 1413-1424Anker S.D. Butler J. Filippatos G. et al.

Empagliflozin in heart failure with a preserved ejection fraction.

N Engl J Med. 385: 1451-1461Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.

Dapagliflozin in patients with chronic kidney disease.

N Engl J Med. 383: 1436-1446Kawamori R. Haneda M. Suzaki K. et al.

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.

Diabetes Obes Metab. 20: 2200-2209Sone H. Kaneko T. Shiki K. et al.

Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Diabetes Obes Metab. 22: 417-426Bonaca M.P. Wiviott S.D. Zelniker T.A. et al.

Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58.

Circulation. 142: 734-747Neal B. Perkovic V. Mahaffey K.W. et al.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

N Engl J Med. 377: 644-657Matthews D.R. Li Q. Perkovic V. et al.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program.

Diabetologia. 62: 926-938Arnott C. Huang Y. Neuen B.L. et al.

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.

Diabetes Obes Metab. 22: 1753-1766Heyward J. Mansour O. Olson L. et al.

Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis.

PLoS one. 15: e0234065

Lin C, Zhu X, Cai X, et al. SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol. 2021;20(1):91.

Dicembrini I. Tomberli B. Nreu B. et al.

Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.

Diabetes Res Clin Pract. 153: 138-144Zelniker T.A. Wiviott S.D. Raz I. et al.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Lancet. 393: 31-39Li D. Yang J.Y. Wang T. et al.

Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials.

Diabetes Metab. 44: 410-414Rådholm K. Wu J.H. Wong M.G. et al.

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.

Diabetes Res Clin Pract. 140: 118-128Tsapas A. Avgerinos I. Karagiannis T. et al.

Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis.

Ann Intern Med. 173: 278-286Miyashita S. Kuno T. Takagi H. et al.

Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials.

Diabetes Res Clin Pract. 163: 108136Palmer S.C. Tendal B. Mustafa R.A. et al.

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

BMJ. 372: m4573

Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals.

Diabetes Obes Metab. 22: 2348-2355Ryan P.B. Buse J.B. Schuemie M.J. et al.

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D).

Diabetes Obes Metab. 20: 2585-2597Yuan Z. DeFalco F.J. Ryan P.B. et al.

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study.

Diabetes Obes Metab. 20: 582-589Fralick M. Kim S.C. Schneeweiss S. et al.

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.

BMJ. 370: m2812Udell J.A. Yuan Z. Rush T. et al.

Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world).

Circulation. 137: 1450-1459Chang H.Y. Singh S. Mansour O. et al.

Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes.

JAMA Intern Med. 178: 1190-1198Ueda P. Svanström H. Melbye M. et al.

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.

BMJ. 363: k4365Yang J.Y. Wang T. Pate V. et al.

Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers.

Diabetes Obes Metab. 21: 1223-1236Patorno E. Pawar A. Bessette L.G. et al.

Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults.

Diabetes Care. 44: 826-835Paul S.K. Bhatt D.L. Montvida O.

The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.

Eur Heart J. 42: 1728-1738Vlachopoulos C. Terentes-Printzios D. Tsioufis K.

Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly.

Eur Heart J. 42: 1739-1741Dawwas G.K. Smith S.M. Park H.

Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.

Diabetes Obes Metab. 21: 28-36Chang H.Y. Chou Y.Y. Tang W. et al.

Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan.

Scientific Rep. 11: 7000Rodionov R.N. Peters F. Marschall U. et al.

Initiation of SGLT2 inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: a health claims data analysis.

Eur J Vasc Endovasc Surg. 62: 981-990Verma S. Mazer C.D. Al-Omran M. et al.

Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME.

Circulation. 137: 405-407

Reduced mortality with sodium-glucose cotransporter-2 inhibitors in observational studies: avoiding immortal time bias.

Circulation. 137: 1432-1434Potier L. Mohammedi K. Velho G. et al.

SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis.

Cardiovasc Diabetol. 20: 107

Coordinators for the ACRGTA, lipid-lowering treatment to prevent heart attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

JAMA. 288: 2981-2997Brown M.J. Palmer C.R. Castaigne A. et al.

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT).

Lancet. 356: 366-372Erkens J.A. Klungel O.H. Stolk R.P. et al.

Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients.

Pharmacoepidemiol Drug Saf. 13: 139-146Sherman S.E. Bell G.I. Teoh H. et al.

Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia.

JACC Basic Transl Sci. 3: 327-329Inzucchi S.E. Zinman B. Fitchett D. et al.

How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial.

Diabetes Care. 41: 356-363Terauchi Y. Tamura M. Senda M. et al.

Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).

Diabetes Obes Metab. 20: 1176-1185Pollock C. Stefansson B. Reyner D. et al.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Lancet Diabetes Endocrinol. 7: 429-441Kohler S. Zeller C. Iliev H. et al.

Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials.

Adv Ther. 34: 1707-1726Yabe D. Yasui A. Ji L. et al.

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: pooled analysis of phase I-III clinical trials.

J Diabetes Investig. 10: 418-428Kashiwagi A. Shestakova M.V. Ito Y. et al.

Safety of ipragliflozin in patients with type 2 diabetes mellitus: pooled Analysis of Phase II/III/IV Clinical Trials.

Diabetes Ther. 10: 2201-2217Dorsey-Treviño E.G. González-González J.G. Alvarez-Villalobos N. et al.

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis.

J Endocrinol Invest. 43: 289-304Qiu M. Ding L.L. Zhang M. et al.

Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors.

Diab Vasc Dis Res. 18 ()McGuire D.K. Shih W.J. Cosentino F. et al.

Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.

JAMA Cardiol. 6: 148-158Udell J.A. Yuan Z. Rush T. et al.

Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the easel population-based cohort study.

Circulation. 137: 1450-1459Adimadhyam S. Lee T.A. Calip G.S. et al.

Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.

Diabetes Obes Metab. 20: 2792-2799Yu O.H.Y. Dell'Aniello S. Shah B.R. et al.

Sodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study.

Diabetes care. 43: 2444-2452Udell J.A. Yuan Z. Ryan P. et al.

Cardiovascular outcomes and mortality after initiation of canagliflozin: analyses from the EASEL study.

Endocrinol Diabetes Metab. 3: e00096Werkman N.C.C. Nielen J.T.H. van den Bergh JPW et al.

Use of sodium-glucose co-transporter-2-inhibitors (SGLT2-Is) and risk of lower limb amputation.

Curr Drug Saf. 16: 62-72